Mr Hayden Coleman > Dechert LLP > New York, United States > Lawyer Profile
Dechert LLP Offices
Dechert LLP
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
NEW YORK
United States
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
NEW YORK
United States
- Firm Profile
- Go to...
Mr Hayden Coleman
+1 212 698 3551 hayden.coleman@dechert.com
Work Department
Product Liability and Mass Torts
Position
Partner
Career
Hayden A. Coleman focuses his practice on representing pharmaceutical, consumer goods and insurance companies facing all forms of aggregate litigation, including class actions, mass tort actions, qui tam and governmental lawsuits. Mr. Coleman has over 20 years of experience representing clients at the trial and appellate levels in matters concerning consumer fraud, false advertising, RICO and product liability claims.
Mr. Coleman has worked extensively in federal and state appellate courts writing briefs in appeals before the Second, Fifth, Sixth and Ninth Circuits. He has lectured and written on topics relating to class actions, product liability and the False Claims Act.
Memberships
- Law360‘s Product Liability Editorial Advisory Board
Education
- State University of New York at Albany, B.A., 1985, cum laude, Dean’s List
- Fordham University School of Law, J.D., 1996, cum laude, Fordham Law Review, Dean’s List, Order of the Coif
Top Tier Firm Rankings
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate finance
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Finance > Structured finance: securitization
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > E-discovery
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Tax > International tax
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: transactional
- Dispute resolution > International arbitration
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Finance > Capital markets: high-yield debt offerings
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Financial services litigation